Tumor Ablation Market Size, Share Global Analysis Report, 2022 – 2030

Industry Insights

[225+ Pages Report] According to the report published by Facts and Factors, the global tumor ablation market size was worth around USD 1.35 billion in 2021 and is predicted to grow to around USD 4.69 billion by 2030 with a compound annual growth rate (CAGR) of roughly 13.59% between 2022 and 2030. The report analyzes the global tumor ablation market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the tumor ablation market.

Market Overview

Tumor ablation is cancer treating minimally invasive surgical process that is used to treat solid cancers. Different types of probes are used to either freeze or burn the cancer cells without the patient requiring them to undergo a surgical process. With tumor ablation techniques, other methodologies are used like computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound (US) to allow the medical professional in positioning the needle probe at the exact spot where the tumor exists. To conduct the ablation process, a tiny hole that is not more than 3 millimeters is required for the probe to enter the body and once the probe has reached the cancer site, external generators are used to freeze or burn cancer. The efficiency of the technique is dependent on several factors including the accessibility of the probe to cancer site and the size of the tumor.

Key Insights

• As per the analysis shared by our research analyst, the global tumor ablation market is estimated to grow annually at a CAGR of around 13.59% over the forecast period (2022-2030)
• In terms of revenue, the global tumor ablation size was valued at around USD 1.35 billion in 2021 and is projected to reach USD 4.69 billion, by 2030.
• The global tumor ablation market is projected to grow at a significant rate due to the growing number of patients with lung cancer
• Based on treatment segmentation, surgical ablation was predicted to show maximum market share in the year 2021
• Based on application segmentation, liver cancer was the leading application in 2021
• On the basis of region, North America was the leading revenue generator in 2021

Growth Drivers

• Growing cases of lung cancer to propel market demand

The global tumor ablation market is projected to grow owing to the increasing number of patients with lung cancer, which begins in the lung and may spread to surrounding parts of the body including lymph nodes and other organs like the brain. It is possible for cancer from other body parts to enter the lungs and this is known as metastases which refers to cancer spreading from one organ to another. Lung cancer can mainly be classified into two types of cells called non-small cells and small cells. Both of the cells grow in different manners and have to be treated differently. Lung cancer is considered a leading cause of death due to cancer in general. If skin cancer is not considered, it ranks second in the list of most diagnosed cancer amongst men and women in the US.

One of the leading causes of lung cancer is smoking, however, it can also be caused due to tobacco, exposure to asbestos, or inhaling secondhand smoke. The associated symptoms are also different from one person to another and most people may not have any symptoms till cancer has reached an advanced state, which is what makes it difficult to treat. As per estimates by the American Cancer Society, there were around 236,740 cases of lung cancer in 2022.

Restraints

• Limitations related to the type of cancer that can be treated to restrict market expansion

One of the leading causes that potentially restricts global market growth is the limitation of tumor ablation methods in terms of the treatment of different types of cancer. Currently, only a certain set of cancer cells can be killed using tumor ablation and it cannot be used to treat a large number of other cancers like skin, ovarian, and thyroid which are also registering a surging increase in the number of affected patients. The risk ratio of a woman contracting ovarian cancer in her lifetime is around 1:78.

Opportunities

• Growing demand for minimally invasive techniques to provide growth opportunities

The disease of cancer is in itself a very stressful medical condition as it not only impacts the physical state of the patient but mental health as well along with emotional stress on family and friends. It can lead to financial problems in certain cases. Hence most cancer patients prefer treatment that can in certain amounts reduce the tension surrounding the treatment process. For instance, chemotherapy may cause numbness, a burning sensation, or shooting pain. To avoid the after-effects of such treatment, patients are getting more inclined toward non-invasive or minimally invasive treatment techniques.

Challenges

• Lack of infrastructure to act as a major challenge

The global tumor ablation market players face challenges in terms of the absence of adequate infrastructure to conduct tumor ablation procedures. The absence is a result of multiple factors like a shortage of trained professionals, insufficient awareness, and non-availability of adequate funds. War-torn countries or regions with slow economic growth are at the forefront of this challenge that the global healthcare community needs to work on.

Segmentation Analysis

The global tumor ablation market is segmented based on application, technology, treatment, and others

Based on application, the global market segments are liver cancer, kidney cancer, lung cancer, breast cancer, and prostate cancer. The global market was dominated by the liver cancer segment in 2021 due to the growing prevalence of the condition as well as the high output efficiency obtained by using tumor ablation techniques in treating cancer cells. The most widely prevalent type of liver cancer is hepatocellular carcinoma which has origins in the main liver cells called hepatocytes. Other types of liver cancer which are less common include hepatoblastoma and intrahepatic cholangiocarcinoma. In almost 43% of the early diagnosed cases of liver cancer, the 5-year survival rate is around 35% as per Cancer.Net.

Based on treatment, the global market is divided into surgical ablation, laparoscopic ablation, and percutaneous ablation. In 2021, the leading segmental growth was observed in the surgical ablation segment due to the high number of patients seeking treatment. Surgical ablation does not take more than 2 to 3 hrs of surgery as opposed to the 10 hours that was the average time consumed for conducting the surgery during the initial phase of ablation technique introduction. Laparoscopic kidney cyst ablation is conducted to remove fragments of symptomatic kidney cysts while securing and preserving the rest of the kidney

Recent Developments:

• In November 2020, Cleveland Clinic became the first medical facility across the globe to use the recent ablation technique for destroying large liver tumors. The patient who underwent the surgery had a 2.4-inch tumor removed from the liver
• In September 2022, Stryker received approval from the US Food and Drug Administration (FDA) authority for OptaBlate, an ablation system for bone tumor

Report Scope

Regional Analysis

• North America to grow with the highest CAGR

The global tumor ablation market is projected to register the highest growth in North America with the US leading the regional market growth due to the high awareness rate amongst the population about different types of cancer as well as the corresponding medical treatment. The US research has been at the forefront of understanding the disease and developing its cure driven by the strong emphasis of the government on cancer study.

The funding for research purposes by the National Cancer Institute and the National Institutes of Health (NIH) has increased significantly in the last few years. It has helped the country fight cancer which can be seen in the declining number of cancer patients in the country. The regional growth may be further driven by the increasing FDA approvals for new ablation devices which are expected to help the healthcare sector deal with and cure cancer.

Competitive Analysis

• Boston Scientific Corporation
• SonaCare Medical
• Ethicon Inc
• Chongqing Haifu Medical Technology Co
• Medtronic Plc
• Neuwave Medical Inc

The global tumor ablation market is segmented as follows:

By Application Segment Analysis

• Liver Cancer
• Kidney Cancer
• Lung Cancer
• Breast Cancer
• Prostate Cancer

By Technology Segment Analysis

• Microwave Ablation
• Radiofrequency Ablation
• Irreversible Electroporation Ablation
• Cryoablation
• Others

By Treatment Segment Analysis

• Surgical Ablation
• Laparoscopic Ablation
• Percutaneous Ablation

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America